Haiqiang Mai

12PUBLICATIONS
38CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSolid tumoursMolecular targetsRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Mar 31, 2026
Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial.

Li-Ting Liu, Xue-Song Sun, Ting-Ting Quan

|Jan 09, 2026
PRMT5 upregulates KCNMB4 expression via histone methylation to promote paclitaxel resistance in advanced nasopharyngeal carcinoma.

Lizhen Liu, Sailan Liu, Yali Wang

|Aug 27, 2025
Correction: Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma.

Kaiqi Lan, Shibing Li, Guodong Jia

|Jul 02, 2025
AK4 promotes nasopharyngeal carcinoma metastasis and chemoresistance by activating NLRP3 inflammatory complex.

Sai-Lan Liu, Li Yuan, Xue-Song Sun

|May 12, 2025
Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma.

Kaiqi Lan, Shibing Li, Guodong Jia

|May 06, 2025
Determining the optimal duration of oral adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma.

Hui Cheng, Jie Chen, Yifu Li

Pageof 2

Frequent Collaborators

4 joint publications

Li Yuan

3 joint publications

Linquan Tang

2 joint publications

Jing Tan

2 joint publications

Chong Zhao